| 崔萌,霍晓颖,陈葆青.吉非替尼联合沙利度胺治疗晚期EGFR突变阳性肺腺癌患者的临床效果研究.[J].中南医学科学杂志.,2017,(5):496-498, 502. |
| 吉非替尼联合沙利度胺治疗晚期EGFR突变阳性肺腺癌患者的临床效果研究 |
| Gefitinib combined with thalidomide in treatment of advanced EGFR mutation positive clinical effect of patients with lung adenocarcinoma |
| 投稿时间：2017-02-19 修订日期：2017-06-17 |
| DOI：10.15972/j.cnki.43-1509/r.2017.05.017 |
| 中文关键词: 吉非替尼 沙利度胺 肺腺癌 表皮生长因子受体 |
| 英文关键词:gefitinib thalidomide lung adenocarcinoma EGFR |
| 基金项目: |
|
| 摘要点击次数: 1056 |
| 全文下载次数: 713 |
| 中文摘要: |
| 目的 探讨吉非替尼联合沙利度胺治疗晚期表皮生长因子受体(EGFR)基因突变阳性肺腺癌患者的临床效果。方法回顾性分析50例EGFR基因敏感突变晚期肺腺癌患者,其中应用吉非替尼单药治疗为对照组,联合应用吉非替尼和沙利度胺治疗为观察组,每组25例,比较两组患者的肿瘤治疗效果、生存情况以及毒副作用。结果与对照组比较,观察组的总体有效率显著增高(32.00% vs 68.00%);疾病控制率显著增高(80.0% vs 52.0%)。随访过程中,观察组的生存曲线较对照组明显抬高,且相关不良反应发生率显著降低。结论采用吉非替尼联合沙利度胺对EGFR基因敏感突变型肺腺癌患者治疗效果较好,不良反应降低。 |
| 英文摘要: |
| Objective To investigate the effect of gefitinib combined with thalidomide in the first-line treatment of advanced pulmonary adenocarcinoma with epidermal growth factor receptor(EGFR)gene mutation.Methods50 cases of advanced pulmonary adenocarcinoma with EGFR mutation were analyzed,observation group (25 cases) was treated with gefitinib combined with thalidomide,and control group was treated with gefitinib (25 cases).The clinical efficacy,survival and toxicity were compared.ResultsCompared to control group,the total effective rate and the disease control rate in observation group was significantly higher (68% vs 32%) and (80% vs 52%).During the follow-up,the survival curve of the observation group was higher,but the rate of adverse reactions was lower.ConclusionGefitinib combined with thalidomide in the first-line treatment of advanced pulmonary adenocarcinoma with EGFR mutation can effectively improve the clinical symptoms,reduce the rate of adverse reactions. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|